TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB91812

Peptide_Name

cMP-C

Activity

Antibacterial Anticancer Antifungal Hemolysis Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

AntiBP3 DRAMP Peptipedia CancerPPD 2.0 dbACP PD_Hemolysis

Sequence_Type

standard

Has_Modification No

Description A 16-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, DRAMP, Peptipedia, and other sources, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

CLNLKALLAVAKKILC-NH2

FASTA

>TPDB91812|Antibacterial;Anticancer;Antifungal;Hemolysis;Toxicity|length=16
CLNLKALLAVAKKILC-NH2

Formula C78H144N20O18S2

Absent Amino Acids RDEQGHMFPSTWY

Common Amino Acids L

Mass 1714.24

PI 9.80

Basic Residues 3

Acidic Residues 0

Hydrophobic Residues 10

Net Charge +3

Boman Index -0.64

Hydrophobicity 1.431

Aliphatic Index 183.12

Half Life

Mammalian: 1.2 hour Yeast: >20 hour E.coli: >10 hour

Extinction Coefficient Cystines 125

Absorbance 280nm 7.29

Polar Residues 3

number

3

A

0

R

1

N

0

D

2

C

0

E

0

Q

0

G

0

H

1

I

5

L

3

K

0

M

0

F

0

P

0

S

0

T

0

W

0

Y

1

V

Amino Acid Distribution

A: 3 R: 0 N: 1 D: 0 C: 2 E: 0 Q: 0 G: 0 H: 0 I: 1 L: 5 K: 3 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 1

Length

16

Formula

C78H144N20O18S2

Mass

1714.24

PI

9.80

Net Charge

+3

Boman Index

-0.64

Hydrophobicity

1.431

C_terminal_Modification

Amidation

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial

Origin

Synthetic

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 7.02 µM

Detail Source Activity Anticancer

Activity Measurement 7.02 µM

Target

Cancer Type Lung Cancer

Cell Line H-157

Tissue Affected Lung

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2018

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 13.87 µM

Detail Source Activity Anticancer

Activity Measurement 13.87 µM

Target

Cancer Type Skin Cancer

Cell Line MDA-MB-435S

Tissue Affected Skin

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2018

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 13.87 µM

Detail Source Activity Anticancer

Activity Measurement 13.87 µM

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Prostate

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2018

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 8.56 µM

Detail Source Activity Anticancer

Activity Measurement 8.56 µM

Target

Cancer Type Brain tumor

Cell Line U-251-MG

Tissue Affected Brain

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2018

Evidence 5 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 13.66 µM

Detail Source Activity Anticancer

Activity Measurement 13.66 µM

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2018